CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel, Shanmugapriya
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. [electronic resource] - Oncotarget Nov 2016 - 78605-78618 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.12522 doi
Aged
Apoptosis--drug effects
Bortezomib--pharmacology
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Chemokine CCL27--metabolism
Drug Resistance, Neoplasm
Female
Humans
Interleukin-10--genetics
Male
Middle Aged
Multiple Myeloma--drug therapy
Proteasome Endopeptidase Complex--metabolism
Proteasome Inhibitors--pharmacology
RNA Interference
Receptor Cross-Talk--drug effects
Receptors, CCR10--genetics
Receptors, Interleukin-10--genetics
Signal Transduction--drug effects
Transfection
Tumor Microenvironment
Xenograft Model Antitumor Assays
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. [electronic resource] - Oncotarget Nov 2016 - 78605-78618 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.12522 doi
Aged
Apoptosis--drug effects
Bortezomib--pharmacology
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Chemokine CCL27--metabolism
Drug Resistance, Neoplasm
Female
Humans
Interleukin-10--genetics
Male
Middle Aged
Multiple Myeloma--drug therapy
Proteasome Endopeptidase Complex--metabolism
Proteasome Inhibitors--pharmacology
RNA Interference
Receptor Cross-Talk--drug effects
Receptors, CCR10--genetics
Receptors, Interleukin-10--genetics
Signal Transduction--drug effects
Transfection
Tumor Microenvironment
Xenograft Model Antitumor Assays